Executive Administration & Musculoskeletal Advisory Board at NYU Langone Orthopedic Hospital | NYU Langone Health
NYU Langone Orthopedic Hospital is led by an executive administration and musculoskeletal advisory board.
Executive Administration at NYU Langone Hospital—Long Island | NYU Langone Health
NYU Winthrop Hospital achieves excellence through the leadership of its senior executives and medical experts.
Executive Administration at NYU Langone Hospital—Suffolk | NYU Langone Health
The chief officers and senior leadership at NYU Langone Hospital—Suffolk oversee the hospital and its outpatient sites.
Executive Physicals | NYU Langone Health
NYU Langone offers executive physicals, providing diagnostic testing and medical referrals.
Exercise & Cardiovascular Wellness Programs | NYU Langone Health
The team at NYU Langone’s Center for the Prevention of Cardiovascular Disease helps people start and maintain a heart-healthy exercise routine.
Exhaled and nasal nitric oxide in children and adults with chronic wet cough
Patients with chronic wet cough will undergo diagnostic evaluation to determine if there is diagnostic utility and an association between their levels of forced exhaled nitric oxide and nasal nitric oxide and ultimate diagnosis of either protracted bacterial bronchitis, cough variant asthma, primary ciliary dyskinesia or cystic fibrosis. The evaluation will be made through the combined use of nasal nitric oxide testing using a non-invasive research device (non FDA approved), forced exhaled nitric oxide testing and further standard of care diagnostic tests and procedures as clinically indicated which may include : blood test, bronchoscopy with bronchoalveolar lavage and endobronchial biopsy, sweat test, CT scans, etc.
Expanded Access Program (EAP) for Obecabtagene-Autoleucel (Obe-Cel) Out-Of-Specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia - AUTO1-OS1
The purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured from their blood cells but the product is deemed OOS (does not meet the specifications to be used commercially). The target patients for this study have limited options for treatment and repeat blood sampling is not feasible. The main aims of this study are (1) to provide adult patients with ALL with access to obe-cel and (2) to describe the safety profile of obe-cel (including CRS, ICANS, serious infections, secondary cancers, and any side effects) within the first 45 days after infusion of OOS obe-cel.This study is a single-arm, open-label, multicenter expanded access program (EAP). The patient population included in this EAP will be adult patients diagnosed with recurring or refractory ALL who were prescribed obe-cel as part of their standard of care and are eligible for use under the approved local prescribing information.
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing how effective and safe it would be to use medicine called nonconforming Idecabtagene Vicleucel (a batch of CAR-T-cell therapy or treatment that is suitable for EAP’s clinical use but not suitable for commercial release) in blood cancer patients who have been prescribed it as part of their routine care. The patients will first receive a medicine called lymphodepleting chemotherapy and then will be treated with the study medicine. The study team will check how the patients are doing and monitor all the patients for side effects and discomforts throughout the study. All patients will have their blood samples taken during the study to see if their blood counts are within acceptable ranges. Doctors will follow up with all patients for up to 3 months after they receive the study medicine to check for safety and to see how the study medicine is changing their cancer.
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing the safety and effectiveness of a medicine called nonconforming lisocabtagene maraleucel (a batch of CAR-T-cell therapy or treatment that is suitable for EAP’s clinical use but not suitable for commercial release) in blood cancer patients who have been prescribed it as part of their routine care. The patients will first receive a medicine called lymphodepleting chemotherapy and then will be treated with the study medicine. The study team will check how the patients are doing and monitor all the patients for side effects and discomforts throughout the study. All patients will have their blood samples taken during the treatment to see if their blood counts are within acceptable ranges. Doctors will follow up with all patients for up to 3 months after they receive the study medicine to check for safety and to see how the study medicine is changing their cancer. Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with nonconforming lisocabtagene maraleucel as the treatment plan.
EXpanding Prenatal cell free DNA screening Across moNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (ß-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of paternal screening.